

## **Paradigm to present at NWR Virtual Healthcare Conference**

---

**Paradigm Biopharmaceuticals Ltd (ASX: PAR) (“Paradigm” or “the Company”)**, a late-stage drug development company focused on delivering new therapies to address unmet medical needs, is pleased to announce that it will present at the NWR Virtual Healthcare Conference.

Chief Medical Officer Dr Donna Skerrett will present to the conference at 11:40am AEDT on Wednesday 19 March 2025.

Shareholders, investors and interested parties are encouraged to register to attend the presentation at the following link:

[https://us02web.zoom.us/webinar/register/WN\\_fdxVjCljRP2\\_QKbwe04WuQ](https://us02web.zoom.us/webinar/register/WN_fdxVjCljRP2_QKbwe04WuQ)

A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via the Company’s website and social media channels.

Questions can be submitted on the day or sent in advance to:

[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

For more information please visit: <https://nwrcommunications.com/healthconf>

A copy of the presentation for the webinar is attached to this announcement or available via the paradigm website:

<https://paradigmbiopharma.com/performance-progress/#announcements>.

### **About Paradigm Biopharmaceuticals**

Paradigm Biopharmaceuticals Ltd. (ASX: PAR) is a late-stage drug development company driven by a purpose to improve patients’ health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm’s focus is developing injectable (subcutaneous) pentosan polysulfate sodium (iPPS) for the treatment of diseases with inflammatory pathogenesis, where the anti-inflammatory and chondroprotective properties of iPPS may be transformative to current care.

Authorised for release by the Paul Rennie, Paradigm Chair and Managing Director Paradigm

To learn more please visit: [www.paradigmbiopharma.com](http://www.paradigmbiopharma.com)

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: [investorrelations@paradigmbiopharma.com](mailto:investorrelations@paradigmbiopharma.com)